Related Articles
COMBINATION THERAPY WITH A NUCLEAR TYPE-II SITE AGONIST AND 5-FLUOROURACIL - INHIBITION OF MAMMARY-TUMOR GROWTH
Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Bioflavonoids, type II [H-3]estradiol binding sites and prostatic cancer cell proliferation
Interaction between nuclear insulin receptor substrate-2 and NF-κB in IGF-1 induces response in breast cancer cells
Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer